Identificación de biomarcadores predictivos de respuesta al tratamiento con R-CHOP en linfoma B difuso de célula grande (LBDCG)

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for approximately 25-35% of them. It is a heterogeneous disease with a variable clinical course that is currently treated with a combination of immuno and chemotherapy (R-CHOP: rituximab + cyclofosfamide, doxorubicin, vincristine and prednisolone). Although the inclusion of immunotherapy (Rituximab) has meant a before and after in the treatment of patients with lymphoma, obtaining complete responses of up to 40-50%, however, a substantial part of the patients relapses, which results in 3-year survival rates of only 30%, and the underlying molecular causes are not yet well known. Therefore, it is relevant to improve the knowledge of the genetic alterations responsible for the refractoriness to the treatment, which finally should lead to new therapeutic proposals. In this project, massive sequencing and bioinformatic analysis are used to: 1) to test the bioinformatic tools, referred to the variant calling and alignment method, with better performance for the detection of said genetic alterations. 2) To detect, identify and study the alterations responsible for the resistance to treatment in relapsed or refractory DLBCL and, similarly, the alterations inherent in ABC or GCB profiles of patients with DLBCL. The purpose of this later biological study is the identification of possible early prognostic biomarkers for this type of lymphoma